Tsao Megan, Hoeg Rasmus, Pecoraro Joshua, Kuehner Megan, Deen Brittany, Guglielmo Julie
University of California, Davis Health (UCDH), Sacramento, CA, USA.
J Oncol Pharm Pract. 2025 Oct;31(7):1046-1050. doi: 10.1177/10781552241276418. Epub 2024 Aug 18.
BackgroundFluid overload (FO) commonly occurs during hospitalization for allogeneic hematopoietic cell transplantation (HCT). Grade 2-4 FO is associated with day +100 non-relapse mortality.1 Post-transplant cyclophosphamide (PTCY) for graft-versus-host disease prevention requires aggressive IV hydration to prevent hemorrhagic cystitis.Materials and MethodsThis is a single-center, retrospective, observational study conducted at an academic medical center via electronic chart review. Included patients received allogeneic HCT followed by PTCY on days +3 and +4. Patients were excluded for age < 18 years or incarceration. Primary endpoints are incidence of Grade 2-4 FO and associated risk factors. Descriptive and inferential statistics (i.e., , used.ResultsOf 97 patients screened, 95 were included and 2 were excluded due to absence of weight measurements needed to grade FO. Median age was 60 years, 66.3% were male, 91.6% received reduced-intensity conditioning, 72.6% received haploidentical HCT, 44.2% were ECOG 0, and 11.6% had diastolic dysfunction. Incidence of grade 2-4 FO was 33.7% (n = 32). Univariate analyses found age (continuous; p = 0.04) and BSA < 1.7 m (p = 0.006) as independent factors associated with grade 2-4 FO. Multivariable regression analysis found 3.3% higher risk with every 1-year increase in age ranging from f 20 to 78 years (OR 1.033, 95% CI 1.001, 1.006; p = 0.0453) and 82.8% lower risk with BSA ≥ 1.7 m (OR 0.172, 95% CI 0.051, 0.588; p = 0.005) after adjusting for co-variates.Conclusion(s)Increasing age and BSA < 1.7 m are risk factors associated with grade 2-4 FO during hospitalization for allogeneic HCT with PTCY.
背景
液体超负荷(FO)在异基因造血细胞移植(HCT)住院期间普遍发生。2-4级FO与移植后100天非复发死亡率相关。1预防移植物抗宿主病的移植后环磷酰胺(PTCY)需要积极的静脉补液以预防出血性膀胱炎。
材料与方法
这是一项在学术医学中心通过电子病历回顾进行的单中心、回顾性、观察性研究。纳入的患者接受异基因HCT,随后在移植后第3天和第4天接受PTCY。年龄<18岁或被监禁的患者被排除。主要终点是2-4级FO的发生率及相关危险因素。采用描述性和推断性统计(即, )。
结果
在筛查的97例患者中,95例被纳入,2例因缺乏分级FO所需的体重测量数据而被排除。中位年龄为60岁,66.3%为男性,91.6%接受减低强度预处理,72.6%接受单倍体相合HCT,44.2%的东部肿瘤协作组(ECOG)体能状态为0,11.6%有舒张功能障碍。2-4级FO的发生率为33.7%(n = 32)。单因素分析发现年龄(连续变量;p = 0.04)和体表面积(BSA)<1.7 m²(p = 0.006)是与2-4级FO相关联的独立因素。多变量回归分析发现,在调整协变量后,年龄每增加1岁(范围为20至78岁),风险升高3.3%(比值比[OR]1.033,95%置信区间[CI]1.001,1.006;p = 0.0453),而BSA≥1.7 m²时风险降低82.8%(OR 0.172,95% CI 0.051,0.588;p = 0.005)。
结论
在接受PTCY的异基因HCT住院期间,年龄增加和BSA<1.7 m²是与2-4级FO相关的危险因素。